Media headlines about Cerecor (NASDAQ:CERC) have trended somewhat positive this week, Accern reports. Accern rates the sentiment of news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cerecor earned a news impact score of 0.14 on Accern’s scale. Accern also assigned news articles about the company an impact score of 46.0446279593897 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Shares of NASDAQ CERC traded up $0.22 during midday trading on Friday, hitting $4.46. 63,546 shares of the company’s stock were exchanged, compared to its average volume of 46,835. The company has a current ratio of 0.91, a quick ratio of 0.67 and a debt-to-equity ratio of 0.59. The company has a market cap of $133.06 million, a PE ratio of 10.62 and a beta of 1.28. Cerecor has a twelve month low of $0.52 and a twelve month high of $5.74.
Cerecor (NASDAQ:CERC) last issued its quarterly earnings data on Friday, May 11th. The company reported ($0.07) earnings per share (EPS) for the quarter. The business had revenue of $4.48 million for the quarter. Cerecor had a return on equity of 41.38% and a net margin of 15.71%. sell-side analysts forecast that Cerecor will post -0.39 earnings per share for the current fiscal year.
In other Cerecor news, Director Armistice Capital Master Fund acquired 130,000 shares of Cerecor stock in a transaction dated Thursday, May 17th. The stock was acquired at an average cost of $3.60 per share, for a total transaction of $468,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Peter Greenleaf bought 12,500 shares of the business’s stock in a transaction on Friday, May 18th. The stock was purchased at an average price of $3.98 per share, with a total value of $49,750.00. Following the completion of the transaction, the chief executive officer now directly owns 412,500 shares of the company’s stock, valued at $1,641,750. The disclosure for this purchase can be found here. Over the last quarter, insiders have bought 469,404 shares of company stock valued at $1,799,112. Insiders own 80.20% of the company’s stock.
Cerecor Company Profile
Cerecor Inc, a pharmaceutical company, focuses on pediatric health care. Its lead product portfolio includes prescribed dietary supplements, such as Poly-Vi-Flor and Tri-Vi-Flor; and prescription drugs, such as Millipre, Veripred, and Ulesfia for the treatment of inflammation of the skin, joints, lungs, and other organs, as well as asthma, allergies, arthritis, and head lice infestation.
Recommended Story: Short Selling
Receive News & Ratings for Cerecor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerecor and related companies with MarketBeat.com's FREE daily email newsletter.